Panchenko Yu. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

In type 2 diabetes mellitus (T2DM), a cascade of pathological reactions unfolds in the vascular endothelium, which, in turn, is included in the pathogenesis mechanisms and causes the development of complications. The main marker of endothelial function is its hormone – endothelin-1 (ET1). The purpose of study was to investigate the impact of endothelin-1 blood level on development of early persistent relapses of diabetic maculopathy after surgical treatment in patients with type 2 diabetes mellitus. We observed 313 patients T2DM (313 eyes) with DMP and initial (group 1; n=40), moderate or severe nonproliferative (NPDR; group 2; n=92) and proliferative diabetic retinopathy (PDR; group 3; n=181). The severity of retinopathy and DMP was determined in accordance with the recommendations of the American Academy of Ophthalmology (2002). In this study, patients underwent four types of surgical interventions: 78 patients underwent a three-port closed subtotal vitrectomy; 85 patients underwent additional peeling of the inner border membrane; in addition to these methods, 81 patients received panretinal laser coagulation of the retina, and cataract phacoemulsification was performed in 69 patients. The frequency of early of persistent relapses of diabetic maculopathy occurrence after surgical treatment and the impact of endothelin-1 blood level were investigated. In a cohort prospective study (n = 313) in patients with diabetic maculopathy with type 2 diabetes mellites, the pathogenetic significance of high blood level of endotelin-1 before surgical treatment for the occurrence of early persistent relapses of diabetic maculopathy after surgical treatment was shown. A regression model of the effect of endothelin-1 level on the development of such relapses was constructed (area under the ROC diagram AUC = 0.580 ± 0.037; p = 0.032). The critical level of endotelin-1 before surgical treatment, when it becomes possible to develop early persistent relapses of diabetic maculopathy, is 2.417 fmol/ml.

diabetic maculopathy, type 2 diabetes mellites, surgical treatment, relapse, endotelin-1.

1. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34:1508-12.
2. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (the Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:985-1002.
3. Feletou M. The endothelium, part I: multiple functions of the endothelial cells–focus on endothelium-derived vasoactive mediators. In colloquium series on integrated systems physiology: from molecule to function. Morgan Claypool Life Sci. 2011;3:1-306.
4. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-23.
5. Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Current Atherosclerosis Reports. 2005;7:242-8.
6.  Williams B, Mancia G, Spiering W, Rosei EА, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39(33):3021-104.
7. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-90. 8.
8. Tanowitz HB, Huang H, Jelicks LA. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun. 2005;73:2496- 503.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
10. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:685-94.
11. Babik B, Peták F, Agócs S, Blaskovics I, Alács E, Bodó K, et al. Diabetes mellitus: endothelial dysfunction and changes in hemostasis. OrvHetil. 2018;159(33):1335-45.
12. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003;17:1289-91.
13. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2008;4:1061-8.
14. Pasechnikova NV. Diabeticheskaya maculopatia. Sovremennie aspekti patogenesa, kliniki, diagnostici, lecheniya. Kyiv: publishing house «Carbon LTD»; 2010. 154 s. [in Russian].
15. Balashevich LI, Izmailov AS. Diabeticheskaya ophthalmopathia. SPb.: Man; 2012. 396 s. [in Russian].
16. Xiao K, Dong YC, Xiao XG, Liang SZ, Wang J, Qian C, et al. Effect of Pars Plana Vitrectomy With or Without Cataract Surgery in Patients with Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019 Oct;10(5):1859-68.
17. Adamiec-Mroczek J, Oficjalska-Młyńczak J, Misiuk-Hojło M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. Cytokine. 2010 Mar;49(3):269-74.
18. McAuley AK, Sanfilippo PG, Hewitt AW, Liang H, Lamoureux E, Wang JJ, et al. Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis. J Diabetes Complications. 2014 May-Jun;28(3):419-25.
19. Panchenko Yu. Effectiveness off different methods of surgical treatment of diabetic maculopathy in patients with type 2 diabetes. American Science Journal. 2019;2(28):27-34.
20. Mogilevskyy SYu, Panchenko YuO, Ziablitsev SV. Zv’yazok endothelinu-1 z rozvitkom recidiviv pri khirurgichnomu likuvanni diabetichnoi maculopathii pri cukrovomu diabeti 2 tipu. Clinical Endocrinology and Endocrine Surgery. 2019;3:34-42. [in Ukrainian].
21. Chang W, Lajko M, Fawzi AA. Endothelin-1 is associated with fibrosis in proliferative diabetic retinopathy membranes. PLoS One. 2018 Jan 19;13(1):e0191285. DOI: 10.1371/journal.pone.0191285
22. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012 May;37(5):416-20.

«Bulletin of problems biology and medicine» Issue 4 Part 2 (154), 2019 year, 177-181 pages, index UDK 617.735-002-02:616.633.66+616.155.2]-076.5

10.29254/2077-4214-2019-4-2-154-177-181